DM
Figure 4a · Panel A
Panel A 是同一 Figure 4a 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Mack Roach, Jingbin Zhang, Osama Mohamad, Douwe van der Wal, Jeffry P Simko, Sandy DeVries, Huei-Chung Huang, Songwan Joun, Edward M Schaeffer, Todd M Morgan, Jessica Keim-Malpass, Emmalyn Chen, Rikiya Yamashita, Jedidiah M Monson, Farah Naz, James Wallace, Jean-Paul Bahary, Derek Wilke, Sonny Batra, Gregory B Biedermann, Sergio Faria, Lindsay Hwang, Howard M Sandler, Daniel E Spratt, Stephanie L Pugh, Andre Esteva, Phuoc T Tran, Felix Y Feng
JCO Clin Cancer Inform 9 e2400284
PURPOSE: Artificial intelligence (AI) tools could improve clinical decision making or exacerbate inequities because of bias. African American (AA) men reportedly have a worse prognosis for prostate cancer (PCa) and are underrepresented in the development genomic biomarkers. We assess the generalizability of tools developed using a multimodal AI (MMAI) deep learning system using digital histopathology and clinical data from NRG/Radiation Therapy Oncology Group PCa trials across racial subgroups. METHODS: In total, 5,708 patients from five randomized phase III trials were included. Two MMAI algorithms were evaluated: (1) the distant metastasis (DM) MMAI model optimized to predict risk of DM, and (2) the PCa-specific mortality (PCSM) MMAI model optimized to focus on prediction death in the presence of DM (DDM). The prognostic performance of the MMAI algorithms was evaluated in AA and non-AA subgroups using time to DM (primary end point) and time to DDM (secondary end point). Exploratory end points included time to biochemical failure and overall survival with Fine-Gray or Cox proportional hazards models. Cumulative incidence estimates were computed for time-to-event end points and compared using Gray's test. RESULTS: There were 948 (16.6%) AA patients, 4,731 non-AA patients (82.9%), and 29 (0.5%) patients with unknown or missing race status. The DM-MMAI algorithm showed a strong prognostic signal for DM in the AA (subdistribution hazard ratio [sHR], 1.2 [95% CI, 1.0 to 1.3]; P = .007) and non-AA subgroups (sHR, 1.4 [95% CI, 1.3 to 1.5]; P < .001). Similarly, the PCSM-MMAI score showed a strong prognostic signal for DDM in both AA (sHR, 1.3 [95% CI, 1.1 to 1.5]; P = .001) and non-AA subgroups (sHR, 1.5 [95% CI, 1.4 to 1.6]; P < .001), with similar distributions of risk. CONCLUSION: Using cooperative group data sets with a racially diverse population, the MMAI algorithm performed well across racial subgroups without evidence of algorithmic bias.
2 个 Figure · 6 个 KM 面板
Figure 4a and 4b: Estimated risks/cumulative incidence curves by racial subgroups for a) DM and b) DDM endpoint in the full cohort
Figure 4a · Panel A
Panel A 是同一 Figure 4a 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4a · Panel B
Panel B 是同一 Figure 4a 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figures 5a and 5b: Risk stratifications of MMAI algorithms within racial subgroups a) DM-MMAI for DM endpoint and b) PCSM-MMAI for DDM endpoint in the development and test cohorts
Figures 5a and 5b: · Panel DM-MMAI_for_DM_endpoint_-_Development
Panel DM-MMAI_for_DM_endpoint_-_Development 是同一 Figures 5a and 5b: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figures 5a and 5b: · Panel DM-MMAI_for_DM_endpoint_-_Test
Panel DM-MMAI_for_DM_endpoint_-_Test 是同一 Figures 5a and 5b: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figures 5a and 5b: · Panel PCSM-MMAI_for_DDM_endpoint_-_Development
Panel PCSM-MMAI_for_DDM_endpoint_-_Development 是同一 Figures 5a and 5b: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figures 5a and 5b: · Panel PCSM-MMAI_for_DDM_endpoint_-_Test
Panel PCSM-MMAI_for_DDM_endpoint_-_Test 是同一 Figures 5a and 5b: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。